The Influence of Circulating Immune Cell and CA125 Dynamics on Neoadjuvant Therapy Selection for Advanced Ovarian Cancer.

Autor: Lazar A; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Popa AM; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Orlov-Slavu C; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Cotan HT; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Iaciu CI; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Olaru CM; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania., Schreiner OD; Regional Institute of Oncology Iasi, 2-4 General Henri Mathias Berthelot Street, 700483 Iasi, Romania.; Department 3-Medical Sciences, Grigore T. Popa University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.; Department of Electrical Measurements and Materials, Gheorghe Asachi Technical University, 700050 Iasi, Romania., Ciobanu RC; Department of Electrical Measurements and Materials, Gheorghe Asachi Technical University, 700050 Iasi, Romania., Nitipir C; Department 8-Clinical Medicine, Carol Davila University of Medicine and Pharmacy, 8 Sanitary Heroes Boulevard, 050474 Bucharest, Romania.; Department of Medical Oncology, Elias Emergency University Hospital, 17 Bd. Marasti, 011461 Bucharest, Romania.
Jazyk: angličtina
Zdroj: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Aug 09; Vol. 60 (8). Date of Electronic Publication: 2024 Aug 09.
DOI: 10.3390/medicina60081290
Abstrakt: Background and Objectives: Ovarian cancer, including tubal and peritoneal cancer, is the third most common gynecological cancer and the leading cause of death from gynecological malignancies in developed countries. This study explores the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in determining the optimal duration of neoadjuvant chemotherapy (NACT) for advanced ovarian cancer. It also investigates the correlation between NLR dynamics and the KELIM score, a chemosensitivity marker, to enhance individualized therapeutic strategies. Materials and Methods: A total of 79 patients underwent NACT followed by interval debulking surgery (IDS) or palliative care. The data collected included demographic information, tumor characteristics, treatment modalities, and laboratory parameters. The baseline NLR (NLR-T0) and post-therapeutic NLR (NLR-T1) were calculated, and their variation (NLR∆) was analyzed. The KELIM score was determined using CA-125 values. Results: Patients with a high baseline NLR (≥2.5) had significantly worse progression-free survival (PFS) and overall survival (OS) compared to those with a low NLR (<2.5). A negative NLR∆ was associated with poorer PFS and OS. The KELIM score indicated a more effective treatment response, with higher scores correlating with better outcomes. The majority of patients achieved R0 resection, and those with favorable KELIM scores showed improved survival rates. Conclusions: The NLR is a valuable prognostic marker for assessing treatment response and guiding NACT duration in advanced ovarian cancer.
Databáze: MEDLINE
Externí odkaz: